An obscure federal statute is allowing US pharmacies to flood the market with unvetted knockoffs of Ozempic, creating a $1bn market of unbranded weight-loss drugs annually.
Injectable weight-loss drugs including Zepbound, Mounjaro, Wegovy, and Ozempic are in short supply, despite being used by an estimated 15.5 million US adults for weight loss without formal approval.
Collection
[
|
...
]